1. Home
  2. TGE vs EQ Comparison

TGE vs EQ Comparison

Compare TGE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

N/A

Current Price

$1.25

Market Cap

68.3M

ML Signal

N/A

EQ

Equillium Inc.

N/A

Current Price

$1.97

Market Cap

64.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TGE
EQ
Founded
2023
2017
Country
France
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.3M
64.5M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
TGE
EQ
Price
$1.25
$1.97
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.50
AVG Volume (30 Days)
43.6K
563.4K
Earning Date
04-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.47
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.99
N/A
Revenue Growth
N/A
13.89
52 Week Low
$0.78
$0.29
52 Week High
$12.99
$2.70

Technical Indicators

Market Signals
Indicator
TGE
EQ
Relative Strength Index (RSI) 44.29 51.03
Support Level $1.01 $1.22
Resistance Level $1.62 $1.97
Average True Range (ATR) 0.09 0.23
MACD -0.02 -0.03
Stochastic Oscillator 35.84 27.05

Price Performance

Historical Comparison
TGE
EQ

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: